Scholarlink

Purpose of Review <p>Neuropathic pain (NP) remains a therapeutic challenge due to the limited efficacy of conventional pharmacotherapies. This review aims to systematically consolidate the pathogenic role of the P2X7 receptor (P2X7R) in NP and to evaluate emerging translational strategies targeting this channel, including natural compounds, selective antagonists, drug repurposing, cell-based therapies, and neuromodulation.</p> Recent Findings <p>Recent studies indicate that P2X7R is highly expressed in the spinal cord or dorsal root ganglia across multiple preclinical models of neuropathic pain, including peripheral nerve injury, diabetic neuropathy, chemotherapy-induced neuropathy, and postherpetic neuralgia, underscoring its pivotal role in the pathogenesis of neuropathic pain. In preclinical studies, targeting P2X7R with agents such as Brilliant Blue G, A-438079, botulinum toxin A, mesenchymal stem cell-derived secretomes, and high-frequency spinal cord stimulation produces marked, P2X7R-dependent analgesic effects.</p> Summary <p> P2X7R stands out as a promising therapeutic target for neuropathic pain. Future priorities should focus on optimizing P2X7R-targeted pharmacodynamics, developing CNS-penetrant oral antagonists, and exploring combination strategies to maximize analgesic outcomes in NP patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

P2X7 Receptor as a Therapeutic Target for Neuropathic Pain: From Mechanisms to Translational Strategies

  • 期刊论文

  • 发表日期：

    2026年5月19日

查看全文
  • Dan Chen,
  • Shanming Zhang,
  • Yanan Guo,
  • Xinrui Zhao,
  • Peng Mao,
  • Xiangjun Hai,
  • Zhanli Yang,
  • Guanghai Zhao

摘要

Purpose of Review

Neuropathic pain (NP) remains a therapeutic challenge due to the limited efficacy of conventional pharmacotherapies. This review aims to systematically consolidate the pathogenic role of the P2X7 receptor (P2X7R) in NP and to evaluate emerging translational strategies targeting this channel, including natural compounds, selective antagonists, drug repurposing, cell-based therapies, and neuromodulation.

Recent Findings

Recent studies indicate that P2X7R is highly expressed in the spinal cord or dorsal root ganglia across multiple preclinical models of neuropathic pain, including peripheral nerve injury, diabetic neuropathy, chemotherapy-induced neuropathy, and postherpetic neuralgia, underscoring its pivotal role in the pathogenesis of neuropathic pain. In preclinical studies, targeting P2X7R with agents such as Brilliant Blue G, A-438079, botulinum toxin A, mesenchymal stem cell-derived secretomes, and high-frequency spinal cord stimulation produces marked, P2X7R-dependent analgesic effects.

Summary

P2X7R stands out as a promising therapeutic target for neuropathic pain. Future priorities should focus on optimizing P2X7R-targeted pharmacodynamics, developing CNS-penetrant oral antagonists, and exploring combination strategies to maximize analgesic outcomes in NP patients.